Zomedica publishes white paper on opportunities for PulseVet therapy

Zomedica recently released a white paper showcasing the effectiveness of PulseVet therapy for treating Exercise Induced Pulmonary Hemorrhage in quarter horses. In addition, the paper highlights that PulseVet therapy offers a potential non-invasive, drug-free treatment option for horses suffering from equine asthma, paving the way for new sales opportunities beyond the technology’s historical applications. “PulseVet therapy is well-established in treating orthopedic issues like osteoarthritis. Its effectiveness in treating lung conditions and asthma opens a new field of potential benefits, highlighting that we are just beginning to understand the potential for this energy-based treatment technology,” said the study’s author, Dr. Beau Whitaker of Brazos Valley Equine Hospital in Salado, TX. PulseVet therapy uses high-energy sound waves to stimulate cells, promoting the release of healing growth factors. This process reduces inflammation, enhances blood flow, increases bone density, and accelerates healing. With an estimated market potential of $1 billion in capital equipment sales and $150 million in annual recurring revenue, the PulseVet system represents a substantial growth opportunity for Zomedica. The white paper demonstrates the potential to extend PulseVet’s therapeutic use into new markets, including equine lung conditions and asthma, making it a vital component of Zomedica’s growth strategy.